产品名称
C26-A6, ≥98% (HPLC)
InChI key
HLRMNXITZQAUIH-UHFFFAOYSA-N
SMILES string
O=S(NC1=CC=CN2N=C(C)N=C12)(C3=CC(Cl)=CC=C3OC)=O
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (Warmed)
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
A26-A6 is a MTDH-SND1 interaction blocker (IC50 = 2.4 μM by cell-free & 12.3 μM by cellular split-luc assay) that competes against metadherin (MTDH; AEG-1; LYRIC) for staphylococcal nuclease domain-containing 1 (SND1) binding, thereby preventing MTDH-SND1 complex from suppressing antitumor T cell responses. A26-A6 inhibits PyMT tumor sphere formation in cultures (IC50 <200 μM) in a MTDH- and SND1-dependent manner and exhibits in vivo efficacy against breast tumor growth and metastasis in mice in vivo (15 mg/kg/d i.v. 5d/wk), including the murine PyMT model, and human breast cancer xenografts (PDX, HCI-001, SCP28).
Metadherin-staphylococcal nuclease domain-containing 1 (MTDH-SND1) interaction inhibitor with anti-triple-negative breast cancer (TNBC) efficacy in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Minhong Shen et al.
Nature cancer, 3(1), 43-59 (2022-02-06)
Metastatic breast cancer is a leading health burden worldwide. Previous studies have shown that metadherin (MTDH) promotes breast cancer initiation, metastasis and therapy resistance; however, the therapeutic potential of targeting MTDH remains largely unexplored. Here, we used genetically modified mice
Minhong Shen et al.
Nature cancer, 3(1), 60-74 (2022-02-06)
Despite increased overall survival rates, curative options for metastatic breast cancer remain limited. We have previously shown that metadherin (MTDH) is frequently overexpressed in poor prognosis breast cancer, where it promotes metastasis and therapy resistance through its interaction with staphylococcal
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持